Kadcyla | search
Click here to view Kadcyla news from 60+ newspapers.
Bookmark or Share- Kadcyla: Side Effects, Dosage & Uses - Drugs.comKadcyla is used to treat HER2-positive breast cancer. Kadcyla is used both for early breast cancer and for breast cancer that has spread to other parts of the body (metastatic). Kadcyla is usually given after other cancer medications have been tried without success. Kadcyla should not be used in place of Herceptin (trastuzumab). Warnings
- Kadcyla | Chemotherapy Drug Information | Chemocare.comKadcyla™ is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death. Kadcyla™ incorporates the HER2 targeted actions of trastuzumab with the microtubule inhibitor DM1 (a maytansine derivative).
- KADCYLA® (ado-trastuzumab emtansine) in HER2+ Breast CancerKADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin ®) and there is cancer remaining in the tissue removed during surgery. Patients are selected for therapy based on an FDA-approved test for KADCYLA.
- Trastuzumab emtansine (Kadcyla) - Cancer Research UKIt is also known by its brand name Kadcyla and TDM1. It is a treatment for: • breast cancer that has spread or come back within 6 months of finishing treatment (advanced breast cancer) • early breast cancer, after surgery if there are still some cancer cells left in the lymph nodes or breast. Trastuzumab emtansine is a combination of the drug trastuzumab (also known by its brand name Herceptin) and a drug called emtansine.
- Kadcyla: Package Insert / Prescribing Information - Drugs.comKadcyla, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based treatment. Select patients for therapy based on an FDA-approved companion diagnostic for Kadcyla [see Dosage and Administration (2.1)].
More
